- Home
- AGIO vs SPHR Comparison
AGIO vs SPHR Comparison
Compare AGIO & SPHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- SPHR
- Stock Information
- Founded
- AGIO 2007
- SPHR 2020
- Country
- AGIO United States
- SPHR United States
- Employees
- AGIO N/A
- SPHR N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- SPHR Services-Misc. Amusement & Recreation
- Sector
- AGIO Health Care
- SPHR Consumer Discretionary
- Exchange
- AGIO Nasdaq
- SPHR Nasdaq
- Market Cap
- AGIO 1.4B
- SPHR 1.4B
- IPO Year
- AGIO 2013
- SPHR N/A
- Fundamental
- Price
- AGIO $32.09
- SPHR $37.78
- Analyst Decision
- AGIO Buy
- SPHR Buy
- Analyst Count
- AGIO 8
- SPHR 10
- Target Price
- AGIO $56.00
- SPHR $46.70
- AVG Volume (30 Days)
- AGIO 550.4K
- SPHR 793.0K
- Earning Date
- AGIO 05-01-2025
- SPHR 05-08-2025
- Dividend Yield
- AGIO N/A
- SPHR N/A
- EPS Growth
- AGIO N/A
- SPHR N/A
- EPS
- AGIO 11.45
- SPHR N/A
- Revenue
- AGIO $37,035,000.00
- SPHR $1,031,650,000.00
- Revenue This Year
- AGIO $27.43
- SPHR $9.75
- Revenue Next Year
- AGIO $189.81
- SPHR $2.12
- P/E Ratio
- AGIO $2.80
- SPHR N/A
- Revenue Growth
- AGIO 25.96
- SPHR 16.89
- 52 Week Low
- AGIO $23.42
- SPHR $23.89
- 52 Week High
- AGIO $62.58
- SPHR $50.88
- Technical
- Relative Strength Index (RSI)
- AGIO 65.51
- SPHR 62.73
- Support Level
- AGIO $29.05
- SPHR $36.91
- Resistance Level
- AGIO $30.45
- SPHR $38.25
- Average True Range (ATR)
- AGIO 1.13
- SPHR 1.45
- MACD
- AGIO 0.33
- SPHR 0.04
- Stochastic Oscillator
- AGIO 91.98
- SPHR 62.58
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.